These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38589675)

  • 21. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
    Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway.
    Wang L; Song G; Chang X; Tan W; Pan J; Zhu X; Liu Z; Qi M; Yu J; Han B
    Oncogene; 2015 Sep; 34(36):4735-45. PubMed ID: 25500540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression.
    Jin R; Yamashita H; Yu X; Wang J; Franco OE; Wang Y; Hayward SW; Matusik RJ
    Oncogene; 2015 Jul; 34(28):3700-10. PubMed ID: 25220414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
    Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
    Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
    Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen receptor (AR) degradation enhancer ASC-J9
    Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C
    Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression.
    Zhu W; Wan F; Xu W; Liu Z; Wang J; Zhang H; Huang S; Ye D
    Clin Transl Med; 2022 Sep; 12(9):e1028. PubMed ID: 36169095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Downregulation of
    Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
    Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.
    Recouvreux MV; Wu JB; Gao AC; Zonis S; Chesnokova V; Bhowmick N; Chung LW; Melmed S
    Endocrinology; 2017 Jul; 158(7):2255-2268. PubMed ID: 28444169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein disulphide-isomerase A2 regulated intracellular tissue factor mobilisation in migrating human vascular smooth muscle cells.
    Peña E; Arderiu G; Badimon L
    Thromb Haemost; 2015 Apr; 113(4):891-902. PubMed ID: 25631539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
    Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
    Singh KB; Ji X; Singh SV
    Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.
    Lin SR; Wen YC; Yeh HL; Jiang KC; Chen WH; Mokgautsi N; Huang J; Chen WY; Liu YN
    Oncogene; 2020 Oct; 39(44):6757-6775. PubMed ID: 32963351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.
    Gowda PS; Deng JD; Mishra S; Bandyopadhyay A; Liang S; Lin S; Mahalingam D; Sun LZ
    Mol Cancer Res; 2013 Nov; 11(11):1448-61. PubMed ID: 23989930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
    Khurana N; Talwar S; Chandra PK; Sharma P; Abdel-Mageed AB; Mondal D; Sikka SC
    Int J Oncol; 2016 Oct; 49(4):1609-19. PubMed ID: 27499349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Zoubeidi A; Kuruma H; Fazli L; Lamoureux F; Beraldi E; Monia BP; MacLeod AR; Thüroff JW; Gleave ME
    Mol Cancer Ther; 2011 Feb; 10(2):347-59. PubMed ID: 21216933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.